Experimental drug shows promise in restoring memory in Alzheimer’s model

A paradigm-shifting study from the Centre for Addiction and Mental Health (CAMH) shows an experimental drug, GL-II-73, has the potential to restore memory and cognitive function in a mouse model of Alzheimer’s disease.

Optimi Health, ATMA Sign Letter of Intent To Advance Phase II Clinical Trial Group and Individual Administration Protocol For Major Depressive Disorder | Psychedelic Invest

VANCOUVER, British Columbia, May 22, 2024 (GLOBE NEWSWIRE) — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing

May 22, 2024

Quantum simulation drives breakthrough in drug development

Led by University of Melbourne theoretician and HPC expert Associate Professor Giuseppe Barca, a research team has achieved the first quantum simulation of biological systems

July 31, 2024

DNA aptamer-based sensors can accurately detect trace amounts of fentanyl, heroin, and cocaine

Researchers from North Carolina State University have developed a new generation of high-performance DNA aptamers and highly accurate drug sensors for cocaine and other opioids.

March 5, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.